Lupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy XR Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The product will be manufactured at Lupin's Nagpur facility in India.
Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and metformin hydrochloride is appropriate.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1513.35 |
Dr. Reddys Lab | 6021.10 |
Cipla | 1364.35 |
Zydus Lifesciences | 951.10 |
Lupin | 1601.00 |
View more.. |